<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790062</url>
  </required_header>
  <id_info>
    <org_study_id>F070910007</org_study_id>
    <secondary_id>5K12HD001258-09</secondary_id>
    <nct_id>NCT00790062</nct_id>
  </id_info>
  <brief_title>Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT</brief_title>
  <official_title>Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind 3-arm randomized clinical trial to determine whether higher dose
      oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony
      and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the
      uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of
      maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and
      effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not
      known.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as brief summary. Prospective interim monitoring (stopping) rules will be assessed upon
      recruitment of 2/3rds of the sample size of 1800. Interim review was conducted by a 3-member
      DSMB in January of 2010 and their recommendations were implemented.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment</measure>
    <time_frame>baseline to discharge (2 - 3 days)</time_frame>
    <description>the number of subjects with any treatment of uterineatony or hemorrhage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Women in Each Group With Risk Factors for Atony or Postpartum Hemorrhage</measure>
    <time_frame>Initial hospital discharge (2-3 days)</time_frame>
    <description>In a secondary data analysis, a parsimonious set of independent risk factors for atony or postpartum hemorrhage was established: White, Hispanic, or Other (non-Black of African American) race/ethnicity, preeclampsia, or chorioamnionitus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk to Using Increasing Doses of Oxytocin Based on Pre-specified Risk Factors</measure>
    <time_frame>baseline to discharge (2-3 days)</time_frame>
    <description>The frequency of the primary study outcome is examined in a subgroup of 939 women with risk factors for atony or postpartum hemorrhage. These risk factors are identified as White, Hispanic, or Other (non-Black or African American) race/ethnicity, chorioamnionitis, and preeclampsia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pre- to Post-delivery Hematocrit (%)</measure>
    <time_frame>During delivery hospitalization: Admission hematocrit - post-delivery hematocrit</time_frame>
    <description>change in hematocrit from admission for delivery (baseline) to post-delivery (4 hours-1day postpartum depending on time of delivery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Individual Treatment or Intervention in the Primary Outcome</measure>
    <time_frame>prior to discharge</time_frame>
    <description>the number of individuals with each of the component treatments or individual outcomes in the primary composite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Postpartum Hemorrhage (Clinical Estimate Greater Than 500cc)</measure>
    <time_frame>Initial hospital discharge (2-3 days)</time_frame>
    <description>the number of individuals with a clinically estimated postpartum blood loss of 500cc or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hospital Stays Greater Than 4 Days</measure>
    <time_frame>Initial hospital discharge (2 days or more)</time_frame>
    <description>Number of individuals with prolonged hospitalization defined as 4 days or more prior to initial hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Requiring Hypotension Warranting Pressor Agent or Fluid Bolus</measure>
    <time_frame>Initial hospital discharge (2-3 days or more)</time_frame>
    <description>number of individuals with hypotension leading to administration of a fluid bolus or vasopressor agent (medication given to raise the blood pressure)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1798</enrollment>
  <condition>Uterine Atony</condition>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Oxytocin 10 units/500cc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose only for prophylaxis given over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin 40 units/500cc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin 80U/500cc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose only given over 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>See arms</description>
    <arm_group_label>Oxytocin 10 units/500cc</arm_group_label>
    <arm_group_label>Oxytocin 40 units/500cc</arm_group_label>
    <arm_group_label>Oxytocin 80U/500cc</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 24 weeks, viable pregnancy, singleton or twins

        Exclusion Criteria:

          -  No consent

          -  Contraindication to oxytocin

          -  Antepartum fetal demise

          -  Intrapartum use of concentrated oxytocin

          -  Planned cesarean

          -  DIC or coagulopathy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan T Tita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22227638</url>
    <description>PUBMED Abstract of Results</description>
  </link>
  <results_reference>
    <citation>Tita AT, Szychowski JM, Rouse DJ, Bean CM, Chapman V, Nothern A, Figueroa D, Quinn R, Andrews WW, Hauth JC. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2012 Feb;119(2 Pt 1):293-300. doi: 10.1097/AOG.0b013e318242da74.</citation>
    <PMID>22227638</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>May 30, 2012</results_first_submitted>
  <results_first_submitted_qc>December 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2014</results_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Alan Tita</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Uterine atony</keyword>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>clinical trial</keyword>
  <keyword>Prophylactic oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Uterine Inertia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 1,798 women randomized.</recruitment_details>
      <pre_assignment_details>At planned interim review (n=1,201), enrollment in the 40-unit group was stopped for futility and enrollment continued in the other groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin 10 Units/500cc</title>
        </group>
        <group group_id="P2">
          <title>Oxytocin 40 Units/500cc</title>
          <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
        </group>
        <group group_id="P3">
          <title>Oxytocin 80U/500cc</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="659"/>
                <participants group_id="P2" count="481"/>
                <participants group_id="P3" count="658"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="659"/>
                <participants group_id="P2" count="481"/>
                <participants group_id="P3" count="658"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin 10 Units/500cc</title>
        </group>
        <group group_id="B2">
          <title>Oxytocin 40 Units/500cc</title>
          <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
        </group>
        <group group_id="B3">
          <title>Oxytocin 80U/500cc</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="659"/>
            <count group_id="B2" value="481"/>
            <count group_id="B3" value="658"/>
            <count group_id="B4" value="1798"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="5.4"/>
                    <measurement group_id="B2" value="23.9" spread="5.1"/>
                    <measurement group_id="B3" value="24.4" spread="5.5"/>
                    <measurement group_id="B4" value="24.2" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="659"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="658"/>
                    <measurement group_id="B4" value="1798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="404"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="379"/>
                    <measurement group_id="B4" value="1061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (not specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="659"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="658"/>
                    <measurement group_id="B4" value="1798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment</title>
        <description>the number of subjects with any treatment of uterineatony or hemorrhage.</description>
        <time_frame>baseline to discharge (2 - 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc</title>
            <description>1 dose only for prophylaxsis given over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc</title>
            <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
1 dose only for prophylaxsis given over 1 hour</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc</title>
            <description>1 dose only for prophylaxsis given over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment</title>
          <description>the number of subjects with any treatment of uterineatony or hemorrhage.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Women in Each Group With Risk Factors for Atony or Postpartum Hemorrhage</title>
        <description>In a secondary data analysis, a parsimonious set of independent risk factors for atony or postpartum hemorrhage was established: White, Hispanic, or Other (non-Black of African American) race/ethnicity, preeclampsia, or chorioamnionitus.</description>
        <time_frame>Initial hospital discharge (2-3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc</title>
            <description>1 dose only for prophylaxis given over 1 hour
Oxytocin: See arms</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc</title>
            <description>One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
Oxytocin: See arms</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc</title>
            <description>1 dose only given over 1 hour
Oxytocin: See arms</description>
          </group>
        </group_list>
        <measure>
          <title>Women in Each Group With Risk Factors for Atony or Postpartum Hemorrhage</title>
          <description>In a secondary data analysis, a parsimonious set of independent risk factors for atony or postpartum hemorrhage was established: White, Hispanic, or Other (non-Black of African American) race/ethnicity, preeclampsia, or chorioamnionitus.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pre- to Post-delivery Hematocrit (%)</title>
        <description>change in hematocrit from admission for delivery (baseline) to post-delivery (4 hours-1day postpartum depending on time of delivery)</description>
        <time_frame>During delivery hospitalization: Admission hematocrit - post-delivery hematocrit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc Over 1 Hour</title>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc Over 1 Hour</title>
            <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc Over 1 Hour</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Pre- to Post-delivery Hematocrit (%)</title>
          <description>change in hematocrit from admission for delivery (baseline) to post-delivery (4 hours-1day postpartum depending on time of delivery)</description>
          <units>hematocrit difference (%)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Individual Treatment or Intervention in the Primary Outcome</title>
        <description>the number of individuals with each of the component treatments or individual outcomes in the primary composite.</description>
        <time_frame>prior to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc</title>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc</title>
            <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Individual Treatment or Intervention in the Primary Outcome</title>
          <description>the number of individuals with each of the component treatments or individual outcomes in the primary composite.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Uterotonic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other-Tamponade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other-Arterial embolization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Postpartum Hemorrhage (Clinical Estimate Greater Than 500cc)</title>
        <description>the number of individuals with a clinically estimated postpartum blood loss of 500cc or more</description>
        <time_frame>Initial hospital discharge (2-3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc</title>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc</title>
            <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Postpartum Hemorrhage (Clinical Estimate Greater Than 500cc)</title>
          <description>the number of individuals with a clinically estimated postpartum blood loss of 500cc or more</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hospital Stays Greater Than 4 Days</title>
        <description>Number of individuals with prolonged hospitalization defined as 4 days or more prior to initial hospital discharge</description>
        <time_frame>Initial hospital discharge (2 days or more)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc</title>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc</title>
            <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hospital Stays Greater Than 4 Days</title>
          <description>Number of individuals with prolonged hospitalization defined as 4 days or more prior to initial hospital discharge</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Requiring Hypotension Warranting Pressor Agent or Fluid Bolus</title>
        <description>number of individuals with hypotension leading to administration of a fluid bolus or vasopressor agent (medication given to raise the blood pressure)</description>
        <time_frame>Initial hospital discharge (2-3 days or more)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc</title>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc</title>
            <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Requiring Hypotension Warranting Pressor Agent or Fluid Bolus</title>
          <description>number of individuals with hypotension leading to administration of a fluid bolus or vasopressor agent (medication given to raise the blood pressure)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="659"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pressor agent (medication given to increase BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluid bolus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk to Using Increasing Doses of Oxytocin Based on Pre-specified Risk Factors</title>
        <description>The frequency of the primary study outcome is examined in a subgroup of 939 women with risk factors for atony or postpartum hemorrhage. These risk factors are identified as White, Hispanic, or Other (non-Black or African American) race/ethnicity, chorioamnionitis, and preeclampsia.</description>
        <time_frame>baseline to discharge (2-3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin 10 Units/500cc</title>
            <description>1 dose only for prophylaxis given over 1 hour
Oxytocin: See arms</description>
          </group>
          <group group_id="O2">
            <title>Oxytocin 40 Units/500cc</title>
            <description>One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
Oxytocin: See arms</description>
          </group>
          <group group_id="O3">
            <title>Oxytocin 80U/500cc</title>
            <description>1 dose only given over 1 hour
Oxytocin: See arms</description>
          </group>
        </group_list>
        <measure>
          <title>Risk to Using Increasing Doses of Oxytocin Based on Pre-specified Risk Factors</title>
          <description>The frequency of the primary study outcome is examined in a subgroup of 939 women with risk factors for atony or postpartum hemorrhage. These risk factors are identified as White, Hispanic, or Other (non-Black or African American) race/ethnicity, chorioamnionitis, and preeclampsia.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>ANCOVA</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin 10 Units/500cc</title>
        </group>
        <group group_id="E2">
          <title>Oxytocin 40 Units/500cc</title>
          <description>Per DSMB recommendations, this intermediate arm was stopped Jan 2010.</description>
        </group>
        <group group_id="E3">
          <title>Oxytocin 80U/500cc</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="658"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan T. N. Tita, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>(205) 934-9616</phone>
      <email>atit@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

